MX2021012384A - Proteínas de union triespecíficas y/o trivalentes que utilizan el formato de dominio variable cruzado doble (codv) para el tratamiento de la infección por vih. - Google Patents

Proteínas de union triespecíficas y/o trivalentes que utilizan el formato de dominio variable cruzado doble (codv) para el tratamiento de la infección por vih.

Info

Publication number
MX2021012384A
MX2021012384A MX2021012384A MX2021012384A MX2021012384A MX 2021012384 A MX2021012384 A MX 2021012384A MX 2021012384 A MX2021012384 A MX 2021012384A MX 2021012384 A MX2021012384 A MX 2021012384A MX 2021012384 A MX2021012384 A MX 2021012384A
Authority
MX
Mexico
Prior art keywords
binding proteins
trispecific
cross
dual
variable domain
Prior art date
Application number
MX2021012384A
Other languages
English (en)
Inventor
Christian Beil
Ercole Rao
Ronnie Wei
Peter D Kwong
Jochen Beninga
Joerg Birkenfeld
Zhi- Yong YANG
Gary J Nabel
Ling Xu
Mark Connors
John R Mascola
Richard A Koup
Young Do Kwon
Amarendra Pegu
Mangaiarkarasi Asokan
Qingbo Liu
Paolo Lusso
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MX2021012384A publication Critical patent/MX2021012384A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En el presente documento se proporcionan composiciones que comprenden proteínas de unión triespecíficas y/o trivalentes que comprenden cuatro cadenas polipeptídicas que forman tres sitios de unión a antígeno que se unen específicamente a una o más proteínas diana del VIH, en las que un primer par de polipéptidos que forman la proteína de unión poseen dominios variables dobles que tienen una orientación cruzada, y en donde el segundo par de polipéptidos posee un dominio variable único. También se proporcionan en el presente documento métodos para preparar proteínas de unión triespecíficas y/o trivalentes y usos de dichas proteínas de unión para el tratamiento y/o la prevención del VIH/SIDA.
MX2021012384A 2019-04-09 2020-04-08 Proteínas de union triespecíficas y/o trivalentes que utilizan el formato de dominio variable cruzado doble (codv) para el tratamiento de la infección por vih. MX2021012384A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831415P 2019-04-09 2019-04-09
EP19306312 2019-10-08
PCT/US2020/027313 WO2020210386A1 (en) 2019-04-09 2020-04-08 Trispecific and/or trivalent binding proteins using the cross-over-dual-variable domain (codv) format for treatment of hiv infection

Publications (1)

Publication Number Publication Date
MX2021012384A true MX2021012384A (es) 2022-02-21

Family

ID=70471109

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012384A MX2021012384A (es) 2019-04-09 2020-04-08 Proteínas de union triespecíficas y/o trivalentes que utilizan el formato de dominio variable cruzado doble (codv) para el tratamiento de la infección por vih.

Country Status (14)

Country Link
EP (1) EP3953384A1 (es)
JP (1) JP2022526826A (es)
KR (1) KR20210149796A (es)
CN (1) CN114096561A (es)
AU (1) AU2020273156A1 (es)
BR (1) BR112021020346A2 (es)
CA (1) CA3136147A1 (es)
CO (1) CO2021014988A2 (es)
IL (1) IL286932A (es)
MA (1) MA55609A (es)
MX (1) MX2021012384A (es)
SG (1) SG11202111011SA (es)
TW (1) TW202104274A (es)
WO (1) WO2020210386A1 (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2480572B1 (en) 2009-09-25 2019-01-30 The United States of America, as represented by The Secretary, Department of Health and Human Services Neutralizing antibodies to hiv-1 and their use
WO2012154312A1 (en) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
BR112014010823B1 (pt) 2011-11-07 2021-02-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services anticorpos que se ligam a gp41 e neutralizam o vírus da imunodeficiência humana tipo 1 (hiv-1), seus usos, molécula de ácido nucleico, vetor de expressão, composição, kit, bem como métodos de detecção de infecção pelo hiv-1 e de teste de imunógeno potencial
WO2013086533A1 (en) 2011-12-08 2013-06-13 The United States Of America, As Represented By The Secretary Department Of Health & Human Services Neutralizing antibodies to hiv-1 and their use
WO2013163427A1 (en) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
US20140213772A1 (en) * 2012-12-28 2014-07-31 Abbvie, Inc. Cross-over dual variable domain immunoglobulin constructs
WO2017011414A1 (en) * 2015-07-10 2017-01-19 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
CN117069855A (zh) * 2015-10-25 2023-11-17 赛诺菲 用于预防或治疗hiv感染的三特异性和/或三价结合蛋白
KR20180134378A (ko) 2016-04-13 2018-12-18 사노피 3특이성 및/또는 3가 결합 단백질
WO2019165122A1 (en) * 2018-02-21 2019-08-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
AU2020272839A1 (en) * 2019-04-09 2021-12-02 Sanofi Trispecific binding proteins, methods, and uses thereof
CA3187085A1 (en) * 2020-08-25 2022-03-03 Manuel Baca Multi-specific antigen binding molecules targeting hiv and methods of use

Also Published As

Publication number Publication date
AU2020273156A1 (en) 2021-12-02
IL286932A (en) 2021-10-31
WO2020210386A1 (en) 2020-10-15
CN114096561A (zh) 2022-02-25
TW202104274A (zh) 2021-02-01
SG11202111011SA (en) 2021-11-29
MA55609A (fr) 2022-02-16
EP3953384A1 (en) 2022-02-16
BR112021020346A2 (pt) 2021-12-07
CO2021014988A2 (es) 2022-01-17
KR20210149796A (ko) 2021-12-09
JP2022526826A (ja) 2022-05-26
CA3136147A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
MX2022014631A (es) Proteinas de union triespecificas y/o trivalentes para la prevencion o el tratamiento de la infeccion por vih.
WO2017180913A3 (en) Trispecific and/or trivalent binding proteins
CR20220552A (es) Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
WO2020068752A8 (en) SIRPα BINDING PROTEINS AND METHODS OF USE THEREOF
WO2018134235A8 (en) Improved serum albumin binders
MX2021012386A (es) Proteínas de union triespecíficas, métodos y usos de las mismas.
PH12020500137A1 (en) Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
NZ628625A (en) Polypeptides binding to human complement c5
WO2022167816A3 (en) Antibodies
CA3179819A1 (en) Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
EP4257193A3 (en) Trispecific and/or trivalent binding proteins
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
MX2024002182A (es) Proteinas de union al factor de crecimiento transformante receptor beta ii (tgf-beta-rii).
MX2021012384A (es) Proteínas de union triespecíficas y/o trivalentes que utilizan el formato de dominio variable cruzado doble (codv) para el tratamiento de la infección por vih.
MX2021015356A (es) Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos.
TN2018000137A1 (en) Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
WO2021058711A3 (en) Antigen binding proteins
EA202191078A3 (ru) Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv
WO2020053742A3 (en) Anti-hla-hbv peptide antibodies
EP3771719A8 (en) A peptide binding to tau-protein
AR118602A1 (es) Proteínas de unión triespecíficas y/o trivalentes para el tratamiento de la infección por vih
WO2021081515A3 (en) Compositions and methods for the treatment of human immunodeficiency virus
WO2020247933A3 (en) Peptide inhibitors for the inhibition of hiv capsid